对抗性高血压的诊断和管理
Miguel Camafort1,2, Reinhold Kreutz3,4, Myeong-Chan Cho5
1Hypertensión Unit. Internal Medicine Department, Hospital Clinic de Barcelona, Barcelona, Spain camafort@clinic.cat.
Heart (British Cardiac Society)
|December 22, 2023
概括
抗性高血压需要药物坚持和改变生活方式. 矿物质皮质类受体抗剂,如螺旋,是关键的第四线治疗方法,研究中的新药物.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐性高血压 (RH) 被定义为高血压,尽管最佳的生活方式和三种药物抗高血压疗法.
- 诊断需要坚持确认,办公室外测量,并排除二次原因.
研究的目的:
- 概述抗性高血压的管理方法.
- 讨论当前和新兴的治疗策略.
主要方法:
- 审查当前的指导方针和临床试验数据.
- 专注于生活方式的修改,治疗合理化和附加疗法.
主要成果:
- 改变生活方式 (低/酒精,运动,减肥) 是至关重要的.
- 建议优化现有疗法,并考虑单片药物组合.
- 矿物质皮质类受体抗剂 (MRA),如螺旋,是有效的第四线治疗方法.
- 目前正在对新型MRAs,阿尔多氨酸合成酶抑制剂和内甲蛋白对抗剂进行研究.
结论:
- 抗性高血压的管理涉及到一个多方面的方法.
- 矿物甲类皮质体受体抗剂代表了一个重要的治疗选择.
- 未来的研究有望为新的向疗法提供希望.
相关概念视频
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
Antihypertensive Drugs: Angiotensin II Receptor Blockers
741
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
741
Heart Failure Drugs: Diuretics
394
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171


